Clinical Nurse Specialist Program year 2022 Source: CMS Open Payments, 2026 publication

Carol Bowen

Clinical Nurse Specialist, Psychiatric/Mental Health Newton, MA Clinical Nurse Specialist

NPI 1326059445 CMS profile 11086859

10 Langley Rd, Newton, MA 02459

Open in the dashboard

General payments

$23

1 record reported · program year 2022

Research payments

$0

Paid to them · None reported · program year 2022

Ownership & investment interest

$0

None reported

Through program year 2022, Carol Bowen of Newton, MA is reported in the CMS Open Payments database as having received $23 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 8th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2022 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Bowen
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Carol Bowen were reported at $0. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Carol Bowen Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $153 $44–$540 $132
2022 $23 $207 $60–$748 $149
2023 $0 $197 $55–$898 $160
2024 $0 $189 $49–$804 $164
2025 $0 $245 $78–$929 $169

Breakdown

Who paid General payments · program year 2022
  1. ACADIA Pharmaceuticals Inc $23 1 payment

Every payment, record by record

What the payments were for General payments · program year 2022
  1. Food and Beverage $23 1 payment
Products named General payments · program year 2022
  1. NUPLAZID $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,330

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$29,836

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

10.7%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fetzima Levomilnacipran Hcl Brand 25 $11,433
Olanzapine Generic 92 $3,009
Duloxetine Hcl Generic 51 $2,108
Venlafaxine Hcl Generic 52 $1,852
Divalproex Sodium Generic 76 $1,617
Sertraline Hcl Generic 170 $1,401
Risperidone Generic 88 $1,113
Mirtazapine Generic 83 $1,093
Bupropion Hcl Generic 47 $859
Quetiapine Fumarate Generic 79 $814

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$7,087

Medicare's payments for the services billed

Medicare patients

48

Average age 84

Services billed

79

35 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 75%
Depression 71%
Arthritis 54%
Chronic kidney disease 35%
Cancer 33%
Ischemic heart disease 29%
Osteoporosis 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record